Citations (59)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Wayne L Furman. (2021) Monoclonal Antibody Therapies for High Risk Neuroblastoma. Biologics: Targets and Therapy 15, pages 205-219.
Read now
Read now
Michelle E Keyel & C Patrick Reynolds. (2019) Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy. Biologics: Targets and Therapy 13, pages 1-12.
Read now
Read now
Katie L. Greenwood & Jennifer H. Foster. (2018) The safety of dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma. Expert Opinion on Drug Safety 17:12, pages 1257-1262.
Read now
Read now
Ina Mueller, Karoline Ehlert, Stefanie Endres, Lena Pill, Nikolai Siebert, Silke Kietz, Penelope Brock, Alberto Garaventa, Dominique Valteau-Couanet, Evelyne Janzek, Norbert Hosten, Andreas Zinke, Winfried Barthlen, Emine Varol, Hans Loibner, Ruth Ladenstein & Holger N. Lode. (2018) Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO. mAbs 10:1, pages 55-61.
Read now
Read now
Irene Y. Cheung, Brian H. Kushner, Shakeel Modak, Ellen M. Basu, Stephen S. Roberts & Nai-Kong V. Cheung. (2017) Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival. OncoImmunology 6:11.
Read now
Read now
Nikolai Siebert, Maxi Zumpe, Madlen Jüttner, Sascha Troschke-Meurer & Holger N. Lode. (2017) PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD2 antibody ch14.18/CHO. OncoImmunology 6:10.
Read now
Read now
Sameer Sait & Shakeel Modak. (2017) Anti-GD2 immunotherapy for neuroblastoma. Expert Review of Anticancer Therapy 17:10, pages 889-904.
Read now
Read now
Beate Hintersteiner, Nico Lingg, Peiqing Zhang, Susanto Woen, Kong Meng Hoi, Stefan Stranner, Susanne Wiederkum, Oliver Mutschlechner, Manfred Schuster, Hans Loibner & Alois Jungbauer. (2016) Charge heterogeneity: Basic antibody charge variants with increased binding to Fc receptors. mAbs 8:8, pages 1548-1560.
Read now
Read now
Nikolai Siebert, Christian Jensen, Sascha Troschke-Meurer, Maxi Zumpe, Madlen Jüttner, Karoline Ehlert, Silke Kietz, Ina Müller & Holger N. Lode. (2016) Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival. OncoImmunology 5:11.
Read now
Read now
Nikolai Siebert, Christin Eger, Diana Seidel, Madlen Jüttner, Maxi Zumpe, Danilo Wegner, Silke Kietz, Karoline Ehlert, Gareth J. Veal, Werner Siegmund, Michael Weiss, Hans Loibner, Ruth Ladenstein & Holger N. Lode. (2016) Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2. mAbs 8:3, pages 604-616.
Read now
Read now
Janice M Reichert. (2015) Antibodies to watch in 2015. mAbs 7:1, pages 1-8.
Read now
Read now
Articles from other publishers (48)
Brian H. Kushner, Michael P. LaQuaglia, Fiorella Iglesias Cardenas, Ellen M. Basu, Justin T. Gerstle, Kim Kramer, Stephen S. Roberts, Suzanne L. Wolden, Nai‐Kong V. Cheung & Shakeel Modak. (2023)
Stage
4N
neuroblastoma before and during the era of
anti‐G
D2
immunotherapy
. International Journal of Cancer 153:12, pages 2019-2031.
Crossref
Crossref
Paul T Kennedy, Demetra Zannoupa, Meong Hi Son, Lekh N Dahal & John F Woolley. (2023) Neuroblastoma: an ongoing cold front for cancer immunotherapy. Journal for ImmunoTherapy of Cancer 11:11, pages e007798.
Crossref
Crossref
Ernest Moles, Christopher B. Howard, Pie Huda, Mawar Karsa, Hannah McCalmont, Kathleen Kimpton, Alastair Duly, Yongjuan Chen, Yizhou Huang, Melinda L. Tursky, David MaSonia Bustamante, Russell Pickford, Patrick Connerty, Sofia Omari, Christopher J. Jolly, Swapna JoshiSylvie ShenJohn E. Pimanda, Alla DolnikovLaurence C. Cheung, Rishi S. Kotecha, Murray D. Norris, Michelle Haber, Charles E. de Bock, Klaartje Somers, Richard B. LockKristofer J. Thurecht & Maria Kavallaris. (2023) Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia. Science Translational Medicine 15:696.
Crossref
Crossref
Julia Balaguer, Laura García Hidalgo, Raquel Hladun, Catalina Márquez Vega & Vanesa Pérez Alonso. (2022) Recent Evidence-Based Clinical Guide for the Use of Dinutuximab Beta in Pediatric Patients with Neuroblastoma. Targeted Oncology 18:1, pages 77-93.
Crossref
Crossref
Jung-Tung Hung & Alice L. Yu. 2023. Glycosignals in Cancer. Glycosignals in Cancer
215
238
.
Vassilios Papadakis, Charikleia Kelaidi, Kalliopi Zisaki, Kondylia Antoniadi, Georgios Pitsoulakis & Sophia Polychronopoulou. (2021) Dinutuximab beta‐related severe neurotoxicity: Resolution with the use of plasmapheresis. Pediatric Blood & Cancer 69:4.
Crossref
Crossref
Godfrey Chi-Fung Chan & Carol Matias Chan. (2022) Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma. Biomolecules 12:3, pages 358.
Crossref
Crossref
Meriem Bahri, Sareetha Kailayangiri, Sarah Vermeulen, Natacha Galopin, Claudia Rossig, François Paris, Sophie Fougeray & Stéphane Birklé. (2021) SIRPα-specific monoclonal antibody enables antibody-dependent phagocytosis of neuroblastoma cells. Cancer Immunology, Immunotherapy 71:1, pages 71-83.
Crossref
Crossref
Stefano Mastrangelo, Serena Rivetti, Silvia Triarico, Alberto Romano, Giorgio Attinà, Palma Maurizi & Antonio Ruggiero. (2021) Mechanisms, Characteristics, and Treatment of Neuropathic Pain and Peripheral Neuropathy Associated with Dinutuximab in Neuroblastoma Patients. International Journal of Molecular Sciences 22:23, pages 12648.
Crossref
Crossref
Fatima Shawraba, Hussein Hammoud, Yara Mrad, Zahraa Saker, Youssef Fares, Hayat Harati, Hisham F. Bahmad & Sanaa Nabha. (2021) Biomarkers in Neuroblastoma: An Insight into Their Potential Diagnostic and Prognostic Utilities. Current Treatment Options in Oncology 22:11.
Crossref
Crossref
Mitchell Evers, Marjolein Stip, Kaylee Keller, Hanneke Willemen, Maaike Nederend, Marco Jansen, Chilam Chan, Kevin Budding, Stefan Nierkens, Thomas Valerius, Friederike Meyer-Wentrup, Niels Eijkelkamp & Jeanette Leusen. (2021) Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma. Journal for ImmunoTherapy of Cancer 9:10, pages e003163.
Crossref
Crossref
Nan Li, Madeline R. Spetz, Dan Li & Mitchell Ho. (2021) Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3. Pharmacology & Therapeutics 223, pages 107892.
Crossref
Crossref
Thomas Blom, Roosmarijn Lurvink, Leonie Aleven, Maarten Mensink, Tom Wolfs, Miranda Dierselhuis, Natasha van Eijkelenburg, Kathelijne Kraal, Max van Noesel, Martine van Grotel & Godelieve Tytgat. (2021) Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients. Frontiers in Oncology 10.
Crossref
Crossref
Irene Veneziani, Paola Infante, Elisa Ferretti, Ombretta Melaiu, Cecilia Battistelli, Valeria Lucarini, Mirco Compagnone, Carmine Nicoletti, Aurora Castellano, Stefania Petrini, Marzia Ognibene, Annalisa Pezzolo, Lucia Di Marcotullio, Roberto Bei, Lorenzo Moretta, Vito Pistoia, Doriana Fruci, Vincenzo Barnaba, Franco Locatelli & Loredana Cifaldi. (2021) Nutlin-3a Enhances Natural Killer Cell–Mediated Killing of Neuroblastoma by Restoring p53-Dependent Expression of Ligands for NKG2D and DNAM-1 Receptors. Cancer Immunology Research 9:2, pages 170-183.
Crossref
Crossref
P. Berlanga, C. Pasqualini, U. Pötschger, C. Sangüesa, M.R. Castellani, A. Cañete, R. Luksch, M. Elliot, G. Schreier, M. Kropf, D. Morgenstern, V. Papadakis, S. Ash, E. Ruud, P. Brock, A. Wieczorek, P. Kogner, T. Trahair, P. Ambros, T. Boterberg, V. Castel, D. Valteau-Couanet & R. Ladenstein. (2021) Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience. European Journal of Cancer 144, pages 1-8.
Crossref
Crossref
Filiz Cicek, Sascha Troschke-Meurer, Kiraz Ceylan, Luciana J. Jahns, Maxi Zumpe, Nikolai Siebert, Karoline Ehlert & Holger N. Lode. (2020) Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy. Frontiers in Pediatrics 8.
Crossref
Crossref
T. V. Shamanskaya, N. A. Andreeva, D. T. Utalieva & D. Yu. Kachanov. (2020) Anti-GD2 immunotherapy with the chimeric antibody ch14.18 for high-risk neuroblastoma. Pediatric Hematology/Oncology and Immunopathology 19:3, pages 173-178.
Crossref
Crossref
Julia W. Cohen, Srivandana Akshintala, Eli Kane, Helen Gnanapragasam, Brigitte C. Widemann, Seth M. Steinberg & Nirali N. Shah. (2020) A Systematic Review of Pediatric Phase I Trials in Oncology: Toxicity and Outcomes in the Era of Targeted Therapies. The Oncologist 25:6, pages 532-540.
Crossref
Crossref
Jeong A. Park & Nai-Kong V. Cheung. (2020) Targets and Antibody Formats for Immunotherapy of Neuroblastoma. Journal of Clinical Oncology 38:16, pages 1836-1848.
Crossref
Crossref
Ladenstein, Pötschger, Valteau-Couanet, Luksch, Castel, Ash, Laureys, Brock, Michon, Owens, Trahair, Chi Fung Chan, Ruud, Schroeder, Beck-Popovic, Schreier, Loibner, Ambros, Holmes, Castellani, Gaze, Garaventa, Pearson & Lode. (2020) Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1). Cancers 12:2, pages 309.
Crossref
Crossref
Vanessa Segura & Adela Cañete. 2020. Neuroblastoma. Neuroblastoma
205
212
.
Brian Hutzen, Siddhi Nath Paudel, Meisam Naeimi Kararoudi, Kevin A. Cassady, Dean A. Lee & Timothy P. Cripe. (2019) Immunotherapies for pediatric cancer: current landscape and future perspectives. Cancer and Metastasis Reviews 38:4, pages 573-594.
Crossref
Crossref
Parnian Jabbari, Sara Hanaei & Nima Rezaei. (2019) State of the art in immunotherapy of neuroblastoma. Immunotherapy 11:9, pages 831-850.
Crossref
Crossref
Frank Peinemann, Elvira C van Dalen, Heike Enk & Godelieve AM Tytgat. (2019) Anti-GD2 antibody-containing immunotherapy postconsolidation therapy for people with high-risk neuroblastoma treated with autologous haematopoietic stem cell transplantation. Cochrane Database of Systematic Reviews 2019:4.
Crossref
Crossref
Yu-tong Zhang, Jian Chang, Hong-mei Xu, Ya-nan Li, Xiao-dan Zhong & Zi-ling Liu. (2018) Treatment of Neuroblastoma with a Novel Delayed Intensification Chemotherapy. The Indian Journal of Pediatrics 86:2, pages 126-131.
Crossref
Crossref
John Inge Johnsen, Cecilia Dyberg & Malin Wickström. (2019) Neuroblastoma—A Neural Crest Derived Embryonal Malignancy. Frontiers in Molecular Neuroscience 12.
Crossref
Crossref
Anupa Kudva & Shakeel Modak. 2019. Neuroblastoma. Neuroblastoma
147
173
.
Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, Roberto Luksch, Victoria Castel, Isaac Yaniv, Genevieve Laureys, Penelope Brock, Jean Marie Michon, Cormac Owens, Toby Trahair, Godfrey Chi Fung Chan, Ellen Ruud, Henrik Schroeder, Maja Beck Popovic, Guenter Schreier, Hans Loibner, Peter Ambros, Keith Holmes, Maria Rita Castellani, Mark N Gaze, Alberto Garaventa, Andrew D J Pearson & Holger N Lode. (2018) Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. The Lancet Oncology 19:12, pages 1617-1629.
Crossref
Crossref
Fabio Morandi, Francesco Frassoni, Mirco Ponzoni & Chiara Brignole. (2018) Novel Immunotherapeutic Approaches for Neuroblastoma and Malignant Melanoma. Journal of Immunology Research 2018, pages 1-12.
Crossref
Crossref
Nikolai Siebert, Sascha Troschke-Meurer, Madlen Marx, Maxi Zumpe, Karoline Ehlert, Juliet Gray, Alberto Garaventa, Carla Manzitti, Shifra Ash, Thomas Klingebiel, James Beck, Victoria Castel, Dominique Valteau-Couanet, Hans Loibner, Ruth Ladenstein & Holger Lode. (2018) Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial. Cancers 10:10, pages 387.
Crossref
Crossref
Kate McKeage & Katherine A. Lyseng-Williamson. (2018) Dinutuximab beta in high-risk neuroblastoma: a profile of its use. Drugs & Therapy Perspectives 34:7, pages 281-287.
Crossref
Crossref
Kiraz Ceylan, Luciana J. Jahns, Bjoern N. Lode, Karoline Ehlert, Silke Kietz, Sascha Troschke‐Meurer, Nikolai Siebert & Holger N. Lode. (2018)
Inflammatory response and treatment tolerance of long‐term infusion of the anti‐GD
2
antibody ch14.18/CHO in combination with interleukin‐2 in patients with high‐risk neuroblastoma
. Pediatric Blood & Cancer 65:6.
Crossref
Crossref
John Inge Johnsen, Cecilia Dyberg, Susanne Fransson & Malin Wickström. (2018) Molecular mechanisms and therapeutic targets in neuroblastoma. Pharmacological Research 131, pages 164-176.
Crossref
Crossref
Jennifer E. Gains, Neil J. Sebire, Veronica Moroz, Keith Wheatley & Mark N. Gaze. (2017) Immunohistochemical evaluation of molecular radiotherapy target expression in neuroblastoma tissue. European Journal of Nuclear Medicine and Molecular Imaging 45:3, pages 402-411.
Crossref
Crossref
Ruth Ladenstein, Bieke Lambert, Ulrike Pötschger, Maria-Rita Castellani, Valerie Lewington, Zvi Bar-Sever, Aurore Oudoux, Anna Śliwińska, Katerina Taborska, Lorenzo Biassoni, Gregory A. Yanik, Arlene Naranjo, Marguerite T. Parisi, Barry L. Shulkin, Helen Nadel, Michael J. Gelfand, Katherine K. Matthay, Julie R. Park, Susan G. Kreissman, Dominique Valteau-Couanet & Ariane Boubaker. (2017) Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials. European Journal of Nuclear Medicine and Molecular Imaging 45:2, pages 292-305.
Crossref
Crossref
Kadri Valter, Boris Zhivotovsky & Vladimir Gogvadze. (2018) Cell death-based treatment of neuroblastoma. Cell Death & Disease 9:2.
Crossref
Crossref
Holger N. Lode. 2018. Immunotherapy for Pediatric Malignancies. Immunotherapy for Pediatric Malignancies
117
139
.
Francesco Ceppi, Maja Beck-Popovic, Jean-Pierre Bourquin & Raffaele Renella. (2017) Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot. European Journal of Pediatrics 176:9, pages 1163-1172.
Crossref
Crossref
Ruth Ladenstein, Ulrike Pötschger, Andrew D J Pearson, Penelope Brock, Roberto Luksch, Victoria Castel, Isaac Yaniv, Vassilios Papadakis, Geneviève Laureys, Josef Malis, Walentyna Balwierz, Ellen Ruud, Per Kogner, Henrik Schroeder, Ana Forjaz de Lacerda, Maja Beck-Popovic, Pavel Bician, Miklós Garami, Toby Trahair, Adela Canete, Peter F Ambros, Keith Holmes, Mark Gaze, Günter Schreier, Alberto Garaventa, Gilles Vassal, Jean Michon & Dominique Valteau-Couanet. (2017) Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. The Lancet Oncology 18:4, pages 500-514.
Crossref
Crossref
Amanda Tivnan, Tatjana Heilinger, Joanne M. Ramsey, Gemma O’Connor, Jenny L. Pokorny, Jann N. Sarkaria, Brett W. Stringer, Bryan W. Day, Andrew W. Boyd, Ella L. Kim, Holger N. Lode, Sally-Ann Cryan & Jochen H.M. Prehn. (2017) Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells. Oncotarget 8:10, pages 16605-16620.
Crossref
Crossref
Kathleen Dorris, Chunyan Liu, Dandan Li, Trent R. Hummel, Xia Wang, John Perentesis, Mi-Ok Kim & Maryam Fouladi. (2017) A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials. Pediatric Blood & Cancer 64:3, pages e26258.
Crossref
Crossref
Christin Eger, Nikolai Siebert, Diana Seidel, Maxi Zumpe, Madlen Jüttner, Sven Brandt, Hans-Peter Müller & Holger N. Lode. (2016) Generation and Characterization of a Human/Mouse Chimeric GD2-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma. PLOS ONE 11:3, pages e0150479.
Crossref
Crossref
Gabriel Levy, Michel Bonnevalle, Nathalie Rocourt, Hélène Sudour & Anne-Sophie Defachelles. (2015) Necrotizing Enterocolitis as an Adverse Effect of Recombinant Interleukin-2 and Ch14.18 in Maintenance Therapy for High-risk Neuroblastoma. Journal of Pediatric Hematology/Oncology 37:4, pages e250-e252.
Crossref
Crossref
Fabio Morandi, Michela Croce, Giuliana Cangemi, Sebastiano Barco, Valentina Rigo, Barbara Carlini, Loredana Amoroso, Vito Pistoia, Silvano Ferrini & Maria Valeria Corrias. (2015) IL-10 and ARG-1 Concentrations in Bone Marrow and Peripheral Blood of Metastatic Neuroblastoma Patients Do Not Associate with Clinical Outcome. Journal of Immunology Research 2015, pages 1-9.
Crossref
Crossref
Konstantin Dobrenkov & Nai-Kong V. Cheung. (2014) GD2-Targeted Immunotherapy and Radioimmunotherapy. Seminars in Oncology 41:5, pages 589-612.
Crossref
Crossref
Nikolai Siebert, Diana Seidel, Christin Eger, Madlen Jüttner & Holger N. Lode. (2014) Functional Bioassays for Immune Monitoring of High-Risk Neuroblastoma Patients Treated with ch14.18/CHO Anti-GD2 Antibody. PLoS ONE 9:9, pages e107692.
Crossref
Crossref
Ana P. Berbegall, Eva Villamón, Irene Tadeo, Tommy Martinsson, Adela Cañete, Victoria Castel, Samuel Navarro & Rosa Noguera. (2014) Neuroblastoma after Childhood: Prognostic Relevance of Segmental Chromosome Aberrations, ATRX Protein Status, and Immune Cell Infiltration. Neoplasia 16:6, pages 471-480.
Crossref
Crossref
Nikolai Siebert, Diana Seidel, Christin Eger, Diana Brackrock, Daniel Reker, Manuela Schmidt & Holger N. Lode. (2013) Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab. Journal of Immunological Methods 398-399, pages 51-59.
Crossref
Crossref